ArticleOchsner journal2010
Coenzyme q10 and statin-induced mitochondrial dysfunction.
Article in Ochsner journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Effects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta-Analyses of Randomised Controlled Trials.Endocrinology, diabetes & metabolism · 2026Pooled it
- The efficacy of coenzyme QJournal of cellular and molecular medicine · 2022Pooled it
- Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial.BMC pharmacology & toxicology · 2026Trial
- Effect of coenzyme Q10 supplementation on oxidative stress and clinical outcomes in patients with low levels of coenzyme Q10 admitted to the intensive care unit.Journal of nutritional science · 2021Trial
- Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study.Drug design, development and therapy · 2019Trial
- Beyond Cholesterol Lowering: Clinical Caution, Personalization, and Nutritional Integration in Statin Therapy.Nutrients · 2026Review
- Diagnosis and Management of Statin-Associated Muscle Symptoms.Korean circulation journal · 2025Review
- Adaptation of mitochondrial bioenergetics to coenzyme Q deficiency in human endothelial cells after chronic exposure to bisphosphonates.Scientific reports · 2025Article
- Kidney Toxicity of Drugs for the Heart: An Updated Perspective.Metabolites · 2025Review
- Understanding coenzyme Q.Physiological reviews · 2024Review
- A Defined, Plant-Based Diet and Other Integrative Therapies Improve Functional Status and Ejection Fraction while Reducing Medications in Patients With Heart Failure: A Case Series.American journal of lifestyle medicine · 2024Article
- Risks of using mitoquinone during in vitro maturation and its potential protective effects against lipotoxicity-induced oocyte mitochondrial stress.Journal of assisted reproduction and genetics · 2024Article
- Lifestyle and Lipoprotein(a) Levels: Does a Specific Counseling Make Sense?Journal of clinical medicine · 2024Review
- Combination Therapy of Cuban Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Targeting Glutamate Neurotoxicity through Dietary Manipulation: Potential Treatment for Migraine.Nutrients · 2023Review
- Genetic evidence implicating circulating lipids and lipid drug targets in pterygium.Computational and structural biotechnology journal · 2023Article
- Statin activation of skeletal ryanodine receptors (RyR1) is a class effect but separable from HMG-CoA reductase inhibition.British journal of pharmacology · 2022Article
- The Role of Nutraceutical Supplements, Monacolin K and Astaxanthin, and Diet in Blood Cholesterol Homeostasis in Patients with Myopathy.Biomolecules · 2022Observational
- Ferroptosis: A Promising Therapeutic Target for Neonatal Hypoxic-Ischemic Brain Injury.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coenzyme Q10 is an important factor in mitochondrial respiration. Primary and secondary deficiencies of coenzyme Q10 result in a number of neurologic and myopathic syndromes. Hydroxyl-methylglutaryl coenzyme A reductase inhibitors or statins interfere with the production of mevalonic acid, which is a precursor in the synthesis of coenzyme Q10. The statin medications routinely result in lower coenzyme Q10 levels in the serum. Some studies have also shown reduction of coenzyme Q10 in muscle tissue. Such coenzyme Q10 deficiency may be one mechanism for statin-induced myopathies. However, coenzyme Q10 supplements have not been shown to routinely improve muscle function. Additional research in this area is warranted and discussed in this review.
Indexed as
Identifiers
21603349PMC3096178W2145246002What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.